Immunosuppression in renal transplantation: some aspects for the modern era☆,☆☆
Introduction
Advances in transplant medicine in recent years have helped to avoid or overcome many clinical challenges in renal transplant recipients, most notably reducing the previous high rates of graft loss to acute rejection, ameliorating the toxicity associated with early immunosuppression regimens, and lowering infection-related mortality. As these areas have been addressed, however, new concerns have become apparent in the quest for higher long-term graft survival rates and quality of life for patients. The clinician is faced with an increasingly diverse range of issues to consider when deciding on the optimal immunosuppressive strategy to adopt based on an individual's specific profile. The relative risk of complications such as diabetes mellitus, the emerging problem of polyomavirus-associated nephropathy, time-dependent adequate dosing of adjunctive therapy, avoidance of chronic nephropathy, and use of novel regimens to achieve balanced calcineurin inhibitor (CNI) exposure are all questions that now need to be taken into account as part of post-transplant management. Remaining up-to-date with the latest findings relating to such a variety of complex areas is a demanding task.
Against this background, an international, multidisciplinary meeting was convened in Berlin in June 2007. The objective was to offer a forum in which transplant clinicians could update themselves on state-of-the-art thinking relating to a wide range of today's challenges in the renal transplant population. This review provides a summary of the data that were presented and discussed at the meeting and seeks to give an insight into how the current knowledge base may influence contemporary clinical practice.
Section snippets
Advances in transplantation medicine—past, present, and future
Development of the surgical expertise to transplant solid organs preceded the immunologic advances necessary to control allograft rejection. Thus, instead of having effective immunosuppressive regimens available from the start of the transplant era, the challenge of organ rejection has stimulated immunologic discoveries that now are beginning to be applied to transplantation. Progress in immunosuppression has focused on the introduction of agents with greater efficacy combined with increasing
Efficacy and glucose metabolism disorders: CNIs in renal transplantation
In recent years, long-term graft survival rates after kidney transplantation have remained largely unchanged despite a concurrent reduction in the incidence of acute rejection [6], [7]. Acute rejection is associated with several disadvantages: treatment with antibody preparations impacts negatively on long-term mortality [8]; steroid treatment increases the risk of complications; more intense maintenance immunosuppression is mandated; and additional health care costs are incurred. The effect of
Polyomavirus infection, replication, and disease in renal transplant recipients
Polyomavirus infection typically occurs during childhood, with seroprevalence rates of 65% to 90% by the age of 10 years, and is usually asymptomatic. Individuals with altered immunity, however, can experience high-level replication and may present with urine cytology (“decoy” cells). In renal transplant recipients, polyomavirus-associated nephropathy (PVAN) develops in 5% of patients and leads to graft loss in approximately 50% of cases. The pathogenesis of PVAN is characterized by persisting
Current issues in MPA therapy
With MPA therapy now routine after renal transplantation, there is a growing need to optimize MPA dosing. One important concern relates to gastrointestinal (GI) symptoms and the consequent need for MMF dose changes or withdrawal, which can have a profound impact on graft outcomes. A series of retrospective analyses has shown a significant increase in the risk of acute rejection [29], [30] or graft loss [31], [32], [33], [34] in renal transplant patients receiving a reduction in or
Chronic allograft nephropathy: a clinical syndrome in renal transplantation
Jeremy Chapman of the Centre for Transplant and Renal Research at the University of Sydney, Australia, discussed strategies for early detection of chronic allograft nephropathy (CAN). Accounting for more than a third of graft losses, CAN is the most frequent cause of graft loss after renal transplantation other than patient death [52], [53]. Using the Banff '97 schema, mild CAN (grade I) is observed in almost all grafts by the end of the first year post-transplant [54], with grade II or III CAN
The potential role of PSIs in de novo and early intervention in maintenance transplant patients
One response to the growing demand for donor kidneys has been the introduction of “old-for-old” transplant programs, in which expanded criteria organs from elderly donors are age-matched to recipients. Increasing donor age, however, is associated with deteriorating renal function, a higher prevalence of risk factors for CAN, and greater susceptibility to CNI nephrotoxicity, all of which contribute to the reduced long-term renal function observed with elderly donors [64]. In addition, older
References (79)
- et al.
Immunosuppression: evolution in practice and trends, 1993–2003
Am J Transplant
(2005) - et al.
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era
Am J Transplant
(2004) - et al.
Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome
Am J Transplant
(2007) - et al.
Diabetes mellitus after kidney transplantation in the United States
Am J Transplant
(2003) - et al.
Patient survival after renal transplantation: IV. Impact of post-transplant diabetes
Kidney Int
(2002) - et al.
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events
Kidney Int
(2006) - et al.
New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation
Kidney Int
(2005) - et al.
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients
Am J Transplant
(2003) - et al.
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
Am J Transplant
(2007) - et al.
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction
Am J Transplant
(2005)
Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation
Am J Transplant
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients
Am J Transplant
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study
Am J Transplant
Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection
Clin Biochem
Calcineurin-inhibitor–sparing immunosuppressive protocols
Transplant Proc
Conversion to everolimus in kidney transplant recipients: a safe and simple procedure
Transplant Proc
Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction
Am J Transplant
Everolimus (Certican) in renal transplantation: a review of clinical data, current usage, and future directions
Transplant Reviews
Cyclosporine
N Engl J Med
Cyclosporine as a milestone in transplantation
Transplant Proc
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
Transplantation
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials
Transplantation
Impact of acute rejection therapy on infections and malignancies in renal transplant recipients
Transplantation
PTDM and acute rejection are associated with a similar risk for graft loss
Am J Transplant
Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis
J Am Soc Nephrol
Renal allograft outcomes according to initial immunosuppressive regimen: a five year follow-up of OPTN database
Am J Transplant
Renal graft survival and calcineurin inhibitor
Transplantation
The role of maintenance immunosuppressive regimen in long term kidney transplant outcome
Am J Transplant
Three year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple drug regimen
Transplantation
Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data
BMJ
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients
N Engl J Med
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations
Transplantation
BK viremia level strongly correlates with the extent/pattern of viral nephropathy (BKPVN): implications for a diagnostic cut-off value
Transplantation
Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation
Am J Transplant
Leflunomide for polyomavirus type BV nephropathy
N Engl J Med
Antivirals for the treatment of polyomavirus BK replication
Expert Rev Anti Infect Ther
Impact of mycophenolate mofetil (MMF)–related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients
Clin Transplant
Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
J Am Soc Nephrol
The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation
Clin Transplant
Cited by (18)
The Consistency and Reporting of Quality-of-Life Outcomes in Trials of Immunosuppressive Agents in Kidney Transplantation: A Systematic Review and Meta-analysis
2016, American Journal of Kidney DiseasesCitation Excerpt :However, the risk of bias assessment suggests an improvement in reporting quality (lower risk of bias) with time. Advances in immunosuppression after transplantation have resulted in the incidence of acute rejection being reduced and short-term transplant survival being improved, yet long-term transplant survival rates after kidney transplantation have stayed essentially the same.47 As a consequence, the selection of immunosuppressive drugs best suited to an individual should involve an evaluation of outcomes associated with complications and harms including health outcomes, such as cancer, diabetes, and infections, and QoL.
The effect of immunosuppression on manifestations of sepsis in an animal model of cecal ligation and puncture
2013, Transplantation ProceedingsCitation Excerpt :A variety of immunosuppressive protocols have been used to treat malignancies, autoimmune diseases, and intestinal inflammation, as well as rejection prophylaxis in solid organ and bone marrow transplantations. The immunosuppressive drugs administered during transplantation are targeted either to a single or several sites in the immune system to prevent or treat organ rejection.26,27 The net state of immunosuppression is a dynamic process determined by all of the factors that contribute to risk for infection.
Significance of polyomavirus detection in urine cytology: an update
2012, Diagnostic HistopathologyCitation Excerpt :There are no FDA-approved assays nor a standardized PCR assay for BK virus: each test must be validated within the laboratory.34 Prospective studies using specified assays have determined BK viraemia thresholds shown to be predictive of BKVAN.8,36 In this context a renal biopsy may be avoided if clinical suspicion of BKVAN is confirmed by PCR test.
Macrophages and T lymphocytes are the predominant cells in intimal arteritis of resected renal allografts undergoing acute rejection
2011, Transplant ImmunologyCitation Excerpt :The immunocytes in acute rejection have been thought to be predominantly lymphocytes [6]. Consequently, a focus of current immunosuppressive regimens is to prevent T-cell activation and infiltration into the transplanted organ [7]. Nevertheless, recent studies have suggested involvement of other cell types, especially in acute vascular rejection [8,9].
Diabetes in organ transplant patients
2008, Medecine des Maladies Metaboliques
- ☆
H.H.H., S.B., and K.B. have received research grants from Novartis; S.C., H.H.H., S.B., W.A., and K.B. have received honoraria from Novartis. R.M. is an employee of Novartis.
- ☆☆
The meeting from which this report is derived was supported by an unrestricted educational grant from Novartis Pharma AG, Basel, Switzerland.